Cargando…
One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient
BACKGROUND: Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV. METHODS: This was a prospective, single-...
Autores principales: | Choo, Hun Gu, Lee, Jin Hae, Oh, Hyun Sub, Kim, Soon Hyun, You, Yong Sung, Kwon, Oh Woong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890830/ https://www.ncbi.nlm.nih.gov/pubmed/33602156 http://dx.doi.org/10.1186/s12886-021-01829-2 |
Ejemplares similares
-
Novel Findings of Polypoidal Choroidal Vasculopathy via Optical Coherence Tomography Angiography
por: Seong, San, et al.
Publicado: (2019) -
One-year Results of Aflibercept Treatment for Polypoidal Choroidal Vasculopathy with Good Visual Acuity
por: Kwon, Ji Min, et al.
Publicado: (2021) -
Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor
por: Moon, Da Ru Chi, et al.
Publicado: (2015) -
Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study
por: Lee, Joo Eun, et al.
Publicado: (2016) -
Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
por: Singh, Sumit Randhir, et al.
Publicado: (2019)